Dashboard

TSX: ATE     CAD ${{ stocks['ATE.TO'].LastPrice }}
Last updated: {{ getStockDate(stocks['ATE.TO']) }} ET
OTCQX: ATBPF   USD ${{ stocks['ATBPF'].LastPrice }}
Last updated: {{ getStockDate(stocks['ATBPF']) }} ET
CAD ${{ getMCap(stocks['ATE.TO']) }}M
MARKET CAP
CAD ${{ stocks['ATE.TO'].YearHigh }}/${{ stocks['ATE.TO'].YearLow }}
52-WEEK HIGH/LOW
{{ stocks['ATE.TO'].AverageDailyVolume3Month }}
AVG. DAILY TRADING VOLUME
11%
INSIDER OWNERSHIP

Corporate Presentation

Learn how Antibe is aiming to change the game in pain and inflammation medicine. Delve into our market opportunity, drug pipeline and the science that underlies our drug platform.

Download Corporate Presentation

Last updated: January 2024

Quarterly & Annual Reports

December 31, 2023

Q3/24: Management’s Discussion & Analysis
December 31, 2023

Q3/24: Quarterly Financial Statements
September 30, 2023

Q2/24: Management’s Discussion & Analysis
September 30, 2023

Q2/24: Quarterly Financial Statements
View financialsRegulatory Filings

ANALYST COVERAGE

FIRM
  • Brookline Capital Markets
  • Echelon Wealth Partners
  • Leede Jones Gable
  • Maxim Group
  • Paradigm Capital
ANALYST
  • Kemp Dolliver, CFA
  • Stefan Quenneville, CFA
  • Douglas Loe, PhD MBA
  • Jason McCarthy, PhD
  • Scott McAuley, PhD
FIRM / ANALYST

Brookline Capital Markets

Kemp Dolliver, CFA

Echelon Wealth Partners

Stefan Quenneville, CFA

Leede Jones Gable

Douglas Loe, PhD MBA

Maxim Group

Jason McCarthy, PhD

Paradigm Capital

Scott McAuley, PhD

The opinions, forecasts and estimates of these analysts do not represent those of Antibe Therapeutics or its directors.

ANALYST COVERAGE

FIRM                                                                                         ANALYST

Brookline Capital Markets                                              Kemp Dolliver, CFA
Canaccord Genuity Capital Markets                           Tania Gonsalves, CFA
Echelon Wealth Partners                                                 Stefan Quenneville, CFA
Leede Jones Gable                                                            Douglas Loe, PhD MBA
Maxim Group                                                                        Jason McCarthy, PhD
Paradigm Capital                                                                Scott McAuley, PhD
Raymond James Ltd.                                                        David Novak, MSc

The opinions, forecasts and estimates of these analysts do not represent those of Antibe Therapeutics or its directors.

Events & Conferences

March 21, 2024 - 815am PT

ASRA Pain Medicine – Moderated Poster Presentation

The Hilton San Diego Bayfront, San Diego, California
March 8, 2024 - 330pm MT

American Academy of Pain Medicine – Poster Presentation

Westin Kierland Resort & Spa, Scottsdale, Arizona
January 25, 2024 - 11am ET

DILIsym: Using QST Predictions to Optimize Your Drug, De-Risk Your Regulatory Submission, and Guide R&D

Virtual Event (recording available following the live event)
January 18, 2024 - 11am ET

New Formulation and Data for Otenaproxesul

Virtual Event (recording available following the live event)
See all events

Recent News

April 19, 2024

Antibe Provides Update on CCAA Proceedings
April 16, 2024

Antibe Announces TSX Delisting Review
April 9, 2024

Antibe Announces Granting of Initial Order under Companies’ Creditors Arrangement Act
Read all news

INVESTOR CONTACT

Christina Cameron
VP Investor Relations
+1 416-577-1443
christina@antibethera.com

Contact us

Attention

This is an external link. Click “OK” to continue.

CANCEL OK